This is unpublished
Biogen
Active Studies
Actively Enrolling
Transplantation
Pinned
Principal Investigator
Nicolae Leca, MD
Funding Agency
Sponsor: HI-BIO Biogen
Status
Active
Actively Enrolling
Investigator
What is the Biogen Study?
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
What are the criteria for the study?
Eligible participants must be 18–74 years old, capable of providing informed consent, and have a biopsy-confirmed active or chronic active AMR within 3 months before randomization.
WHO DO I CONTACT FOR MORE INFORMATION?
Research Coordinator
Nidhi Mehta
E: nidhim3@Nephrology.washington.edu